Pfizer Limited's board meets July 28, 2026, to approve its annual financial results after a mixed fiscal year. While full-year sales grew 10.43% to ₹2,519 crore, net profit for the fourth quarter dropped significantly by 39.7% year-on-year. Investors are focused on the sharp reduction in annual dividends and rising operational costs.
Detailed Coverage
Pfizer Limited, a major player in the Indian pharmaceutical sector, is set to hold a board meeting on July 28, 2026. The meeting will focus on reviewing and approving the financial results for the fourth quarter and the full fiscal year ending March 31, 2026. Ahead of this announcement, the company's stock experienced a minor decline, closing at ₹4,623.60 per share.
The company’s full-year performance shows a clear disconnect between revenue growth and profitability. While annual consolidated sales rose by 10.43% to reach ₹2,519 crore compared to the previous year, the net profit declined by 5.87% to ₹722 crore. This trend indicates that Pfizer India has faced significant pressure on its profit margins during the year, likely due to increased raw material costs or higher spending on operations.
Looking specifically at the fourth quarter ending March 31, 2026, the company reported a standalone profit of ₹199 crore, which is 39.70% lower than the ₹330 crore earned in the same period last year. However, when comparing this to the previous quarter (the three months ending December 2025), the profit showed a rebound of 41.13% from ₹141 crore, even as quarterly sales saw a slight dip of 2.48%. This suggests that the company’s ability to manage costs fluctuates significantly on a quarter-to-quarter basis.
For shareholders, a key point of interest will be the company’s capital allocation policy. The board has announced a dividend of ₹75.00 per share for the fiscal year 2026, which is a sharp reduction from the ₹165.00 dividend paid in the previous year. While the Basic Earnings Per Share (EPS) for the full year improved to ₹157.92 from ₹136.46, the decision to cut the dividend may be a point for investors to analyze when reviewing the company's cash flow needs and future expansion plans.
Pfizer India currently trades with a Price-to-Earnings (P/E) ratio of 29.89 and a Price-to-Book (P/B) ratio of 5.14, with a market capitalization of approximately ₹21,151.92 crore. As the company navigates the current pharmaceutical market, investors will monitor the board’s commentary for explanations regarding the profit margin decline and the strategy behind the lower dividend payout. The company's future ability to maintain sales growth while stabilizing profit margins will remain a primary focus for market participants in the coming quarters.